COVID-19 and Light Chain Amyloidosis: Correspondence

We would like to discuss the article “COVID-19 and Light Chain Amyloidosis (AL), Adding Insult to Injury,”1 published in a recent issue of The American Journal of Medicine. Crees and Stockerl-Goldstein mentioned that “… overlap creates unique challenges in caring for patients with AL which are further compounded by the immunosu ppressive nature of anti-plasma cell therapies, the need for frequent clinical assessments and the exclusion of AL patients from initial COVID-19 vaccine trials…”1 We agree that managing COVID-19 and administering COVID-19 immunization to patients with underlying disease can be difficult.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Letter Source Type: research